Quick Answer
Propanc Biopharma, Inc. reported Net Income of -$58.92 million for fiscal year 2025.
Propanc Biopharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$58.92M -3136.6% |
-$1.82M +31.6% |
-$2.66M -0.1% |
-$2.66M -31.2% |
-$2.03M +57.3% |
-$4.74M +17.7% |
| Diluted EPS | -$14.85 +99.0% |
-$1420.53 -78818.3% |
-$1.80 +96.3% |
-$49.23 | — | — |
| Total Assets | $19.63M +27028.9% |
$72.4K +20.0% |
$60.3K -26.1% |
$81.7K +523.2% |
$13.1K -86.7% |
$98.5K -3.1% |
| Cash and Equivalents | — | — | — | $4.1K +80.4% |
$2.3K -96.6% |
$67.0K |
| Stockholders Equity | $13.91M +468.0% |
-$3.78M -21.2% |
-$3.12M -3.1% |
-$3.02M +1.4% |
-$3.07M +15.8% |
-$3.64M +15.3% |
| R&D Expense | $223.7K -9.8% |
$248.1K +0.1% |
$247.9K -3.2% |
$256.1K +10.9% |
$231.0K +28.3% |
$180.0K -30.9% |
| Operating Income | -$57.28M -3628.9% |
-$1.54M +13.5% |
-$1.78M +10.8% |
-$1.99M -9.9% |
-$1.81M +48.1% |
-$3.49M -33.6% |
| Shares Outstanding | 11.61M +145411.1% |
7,980 -99.9% |
6.03M +2637.1% |
220,351 -98.4% |
14.06M +5345.3% |
258,120 -73.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | December 31, 2025 | -$3.09M | -618.6% | +36.1% |
| Diluted EPS | December 31, 2025 | -$0.30 | +99.1% | +23.1% |
| Total Assets | December 31, 2025 | $15.11M | +19142.3% | -15.9% |
| Cash and Equivalents | March 31, 2023 | $93.2K | -30.4% | +280.9% |
| Stockholders Equity | December 31, 2025 | $10.45M | +351.3% | -27.2% |
| R&D Expense | December 31, 2025 | $20.0K | -63.3% | -66.8% |
| Operating Income | December 31, 2025 | -$3.65M | -1612.8% | +21.8% |
| Shares Outstanding | December 31, 2025 | 13.45M | +92605.3% | +5.0% |
- Propanc Biopharma, Inc. reported Net Income of -$58.92 million for fiscal year 2025.
- Propanc Biopharma, Inc. showed a decrease of -3136.6% in Net Income compared to the prior fiscal year.
- Propanc Biopharma, Inc. reported Diluted EPS of $14.85 per share (loss) for fiscal year 2025.
- Propanc Biopharma, Inc. showed an increase of +99.0% in Diluted EPS compared to the prior fiscal year.
- Propanc Biopharma, Inc. reported Total Assets of $19.63 million for fiscal year 2025.
- Propanc Biopharma, Inc. showed an increase of +27028.9% in Total Assets compared to the prior fiscal year.
- Propanc Biopharma, Inc. reported Cash and Equivalents of $4.1 thousand for fiscal year 2022.
- Propanc Biopharma, Inc. showed an increase of +80.4% in Cash and Equivalents compared to the prior fiscal year.
- Propanc Biopharma, Inc. reported Stockholders Equity of $13.91 million for fiscal year 2025.
- Propanc Biopharma, Inc. showed an increase of +468.0% in Stockholders Equity compared to the prior fiscal year.
- Propanc Biopharma, Inc. reported R&D Expense of $223.7 thousand for fiscal year 2025.
- Propanc Biopharma, Inc. showed a decrease of -9.8% in R&D Expense compared to the prior fiscal year.
- Propanc Biopharma, Inc. reported Operating Income of -$57.28 million for fiscal year 2025.
- Propanc Biopharma, Inc. showed a decrease of -3628.9% in Operating Income compared to the prior fiscal year.
- Propanc Biopharma, Inc. reported Shares Outstanding of 11.61 million shares for fiscal year 2025.
- Propanc Biopharma, Inc. showed an increase of +145411.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: